• Offer Agreement

• Amendment to Offer Agreement

• Registrar Agreement

• Monitoring Agency Agreement

• Cash Escrow and Sponsor Bank Agreement

• Share Escrow Agreement

• Syndicate Agreement

• Underwriting Agreement

• MOA & AOA

• Certificate of Incorporation and Certificate of Conversion

• Resolution dated April 9, 2024 and July 22, 2024 passed by the Board authorising the Offer

• Resolution dated May 25, 2024 passed by the Shareholders authorising the Fresh Issue

• Resolution dated July 26 2024 read with the resolution dated December 6 2024 Selling Shareholders in the Offer for Sale

• Resolution dated July 26, 2024 passed by the Board approving DRHP

• RHP Board Resolution dated December 15, 2024

• Consent letter of the Selling Shareholders for OFS

• Engagement Letter Frost and Sulivan March 29 2024

• Frost and Sullivan report Overview of Global Pharma Market July 24 2024

• Consent letter dated December 7, 2024 issued by Frost & Sullivan

• Share Subscription cum Shareholders Agreement dated January 24, 2022 with Amendment Agreement dated July 03, 2024

• Share swap agreement dated November 2, 2023 and Amendment Agreement dated December 13, 2023

• Share swap agreement dated December 21, 2022

• Share swap agreement dated April 14, 2023 entered into by our Company, Havix and Renosen Pharmaceuticals Private Limited

• Share swap agreement dated April 14, 2023 entered into by our Company, Havix, Aviraj Group LLC, and Aviraj Overseas LLC

• Scheme of Amalgamation

• Examination Report dated November 16, 2024

• Written consent dated December 7, 2024 from Pankaj R. Shah, Statutory Auditors

• Consent dated December 13, 2024 from Ramesh Mahipatram Trivedi, Dev Consultant

• Consent dated July 22, 2024 from Jitendra Shrivastava, independent project expert

• Consent Letters from BRLMs, RTA, Syndicate Members, Bankers, Monitoring Agency, Legal Counsel, Directors and CS

• Corporate Governance certificate dated December 15, 2024

• Certificate dated September 3, 2024 from Tapan Shah, practising company secretary

• Certificate dated December 07, 2024 from PRS certifying WACA

• Certificates dated December 7, 2024 from PRS

• Certificate dated December 13, 2024 from Ramesh Mahipatram Trivedi, Dev Consulant

• Certificate dated December 5, 2024 from Mukesh H. Shah & Co., practicing company secretary

• Report on the statement of possible special tax benefits dated December 07, 2024

• Report on Statement of Special Tax benefits -TAAK Consulting LLC dated December 13 2024

• Valuation report dated November 4, 2022 from Avinash Kothari, Registered Valuer

• Valuation report dated April 1, 2023 from Vikram Shah Immovable property

• Valuation report dated April 1, 2023 from Vikram Shah, Registered Valuer-PM

• Annual Report

• Annual Report for FY 2023-2024

• Annual Report for FY 2022-2023

• Annual Report for FY 2021-2022

• Tripartite agreement dated October 4, 2023, among our Company, NSDL and RTA

• Tripartite agreement dated September 21, 2023, among our Company, CDSL and the RTA

• Certificate on KPI

• Due diligence certificate to SEBI from the BRLMs dated July 26, 2024

• In-principle listing approvals both dated September 27, 2024 from BSE and NSE

• SEBI Final Observation letter dated October 9, 2024 – Senores Pharmaceuticals Limited